6-benzhydryl-2,3-dihydropyridazin-3-one | 172937-96-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-benzhydryl-2,3-dihydropyridazin-3-one
• 英文别名: 6-(diphenylmethyl)pyridazin-3(2H)-one；6-diphenylmethyl-3(2H)-pyridazinone；6-benzhydrylpyridazin-3(2H)-one；3-benzhydryl-1H-pyridazin-6-one
• CAS: 172937-96-1
• 化学式: C₁₇H₁₄N₂O
• 分子量: 262.311
• InChiKey: STMBGKFHQIWILN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-benzhydryl-2,3-dihydropyridazin-3-one 在 18-冠醚-6 、 potassium tert-butylate 、 三溴化硼 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-benzhydryl-2-[[(2S)-5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl]methyl]pyridazin-3-one
  参考文献：
  名称：

  A novel pyridazinone derivative as a nonprostanoid PGI2 agonist

  摘要：

  A novel optically pure pyridazinone derivative was synthesized and identified as a nonprostanoid PGI(2) agonist. It inhibited ADP-induced aggregation of human platelets with an IC50 value of 0.081 muM and has high oral bioavailability (56%) with a long half-life (4.3 h) in rats. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00571-0
• 作为产物：
  描述：

  ethyl 2-hydroxy-4-oxo-5,5-diphenylpentanoate 在 一水合肼 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 15.0h， 以26.3 kg的产率得到6-benzhydryl-2,3-dihydropyridazin-3-one
  参考文献：
  名称：

  Development of a Practical and Scalable Synthesis of a Potent CRTH2 Antagonist

  摘要：

  This contribution describes the process research and development of a practical and scalable synthetic method towards compound 1, which has a potent CRTH2 antagonistic activity. The medicinal chemistry synthetic route and second generation synthetic route had several issues in scale-up synthesis. In contrast, the synthetic method described here does not require purification by column chromatography for all steps, and the formation of impurities is suppressed well. This highly efficient and scalable process was successfully demonstrated in the large-scale synthesis of 1.

  DOI：

  10.1021/op3001492

文献信息

• [EN] MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR DE PROSTACYCLINE (PGI2) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CELUI-CI
  申请人：ARENA PHARM INC

  公开号：WO2010077275A1

  公开（公告）日：2010-07-08

  Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  环己烷衍生物的公式Ia和调节PGI2受体活性的药物组合物。本发明的化合物和药物组合物适用于治疗以下疾病：肺动脉高压（PAH）及相关疾病；血小板聚集；冠心病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤；在血管成形术或冠状动脉搭桥手术个体或房颤患者中形成血栓；动脉粥样硬化；动脉血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼内压异常的眼病；高血压；炎症；银屑病；银屑病关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺病（COPD）。
• Naphthalene derivatives as prostaglandin I.sub.2 agonsists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05763489A1

  公开（公告）日：1998-06-09

  A compound of the formula ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is hydrogen, hydroxy, protected hydroxy, etc., R.sup.4 is hydrogen or halogen, A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene, --R.sup.5 is ##STR2## (in which R.sup.6 is mono(or di or tri)aryl(lower)alkyl and Z is N or CH), etc., and ##STR3## and a pharmaceutically acceptable salt thereof which are useful as medicaments.

  一种化学式为##STR1##的化合物，其中R.sup.1是羧基或保护的羧基，R.sup.2是氢、羟基或保护的羟基，R.sup.3是氢、羟基、保护的羟基等，R.sup.4是氢或卤素，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，--R.sup.5是##STR2##（其中R.sup.6是单（或双或三）芳基（较低）烷基，Z为N或CH），等等，以及##STR3##和其药用盐，可用作药物。
• [EN] NAPHTHALENE DERIVATIVES AS PROSTAGLANDIN I2 AGONISTS<br/>[FR] DERIVES DE NAPHTALENE UTILISES COMME AGONISTES DE LA PROSTAGLANDINE I2
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1995024393A1

  公开（公告）日：1995-09-14

  (EN) A compound of formula (I) wherein, R1 is carboxy or protected carboxy; R2 is hydrogen, hydroxy or protected hydroxy; R3 is hydrogen, hydroxy, protected hydroxy, etc.; R4 is hydrogen or halogen; A1 is lower alkylene; A2 is bond or lower alkylene; -R5 is (a) (in which R6 is mono(or di or tri)aryl(lower)alkyl and Z is N or CH), etc.; and (b) is (c), etc.; and a pharmaceutically acceptable salt thereof which are useful as medicaments.(FR) La présente invention concerne un composé de formule (I) et l'un de ses sels pharmaceutiquement acceptables qui sont utiles comme médicaments. Dans cette formule (I), R1 représente carboxy ou carboxy protégé; R2 représente hydrogène, hydroxy ou hydroxy protégé; R3 représente hydrogène, hydroxy, hydroxy protégé, etc.; R4 représente hydrogène ou halogène; A1 représente alkylène inférieur; A2 représente une liaison ou alkylène inférieur; -R5 a la formule (a). Dans cette formule (a), R6 représente alkyle (inférieur ou non) de mono (di ou tri)aryle; et Z représente N ou CH, etc. et (b) représente (c), etc.

  化合物公式(I)及其药物可接受的盐，作为药物有用，其中，R1表示羧基或保护羧基；R2表示氢、羟基或保护羟基；R3表示氢、羟基、保护羟基等；R4表示氢或卤素；A1表示较低的烷基；A2表示键或较低的烷基；-R5为(a)，其中R6为单（或双或三）芳基（较低）烷基，Z为N或CH等；以及(b)为(c)等。
• POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS
  申请人：Terasaka Tadashi

  公开号：US20100009991A1

  公开（公告）日：2010-01-14

  The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

  本发明涉及一种新型化合物或其盐，该化合物可作为CRTH2拮抗剂使用，特别是作为治疗参与嗜酸性粒细胞的疾病的药物，例如哮喘、过敏性鼻炎、过敏性皮炎、结膜炎、荨麻疹、嗜酸性支气管炎、食物过敏、鼻窦炎炎症、多发性硬化症、血管炎或慢性阻塞性肺疾病（COPD）等疾病。
• Naphthalene derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05863918A1

  公开（公告）日：1999-01-26

  A compound or the formula: ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is hydrogen, hydroxy, protected hydroxy, etc., R.sup.4 is hydrogen or halogen, A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene, --R.sup.5 is ##STR2## (in which R.sup.6 is mono(or di or tri)aryl(lower)alkyl and Z is N or CH), etc., and ##STR3## etc., and a pharmaceutically acceptable salt thereof which are useful as medicaments.

  一种化合物或式子：##STR1## 其中R.sup.1是羧基或保护羧基，R.sup.2是氢，羟基或保护羟基，R.sup.3是氢，羟基，保护羟基等，R.sup.4是氢或卤素，A.sup.1是低级烷基，A.sup.2是键或低级烷基，--R.sup.5是##STR2## （其中R.sup.6是单（或二或三）芳基（低）烷基，Z是N或CH），等等，以及其药学上可接受的盐，可用作药物。